The first presentation, scheduled for November 12 from 7 a.m. to 8:30 p.m. ET, will describe how artificial intelligence (AI)-assisted analysis of NK cell transcriptome and metabolome show that the toxicity of its GDA-201 NAM-enhanced NK cell immunotherapy is based on metabolic modulation, according to the company.

The second presentation, slated for November 13 from 7 a.m. to 8:30 p.m. ET, will share how nicotinamide rejuvenates ex vivo expanded NK cells and enhances their capacity to kill tumors, Gamida Cell said.